Kinsale Capital Group, Inc.
KNSL
$313.61
-3.44%
Kinsale Capital Group, Inc. is a specialty insurance holding company focused on the Excess and Surplus Lines (E&S) market, offering property, casualty, and specialty insurance products to niche sectors such as allied health, healthcare, life sciences, and professional entities. The company has established itself as a disciplined, technology-enabled underwriter in the fragmented E&S space, known for its underwriting profitability and efficient operating model. The current investor narrative centers on the stock's significant derating from its historical highs, driven by concerns over potential margin compression in a competitive insurance market and a broader shift away from premium-valued growth stocks, despite the company's continued strong fundamental performance.…
KNSL
Kinsale Capital Group, Inc.
$313.61
Investment Opinion: Should I buy KNSL Today?
Rating: Hold. The core thesis is that KNSL's exceptional fundamentals are currently overshadowed by negative momentum and sentiment, creating a high-risk, high-potential-reward scenario that requires patience and confirmation of a trend reversal.
Supporting this view, the stock trades at a forward P/E of 14.33x, a significant discount to its recent historical valuation, while generating a 25.7% ROE and 17.3% YoY revenue growth. The implied upside to the 52-week high of $512.76 is substantial (+65%), but the near-term path is clouded by the stock trading just 6% above its 52-week low. Analyst sentiment is mixed with recent downgrades, and the high short interest of 8.5 indicates professional skepticism.
The thesis would upgrade to a Buy on sustained technical recovery above key resistance (e.g., $400) coupled with evidence of margin stability in the next earnings report. It would downgrade to a Sell on a breakdown below the $293.78 support level or a deceleration of revenue growth below 10%. Currently, the stock appears fairly valued to slightly undervalued relative to its own growth profile but remains vulnerable to further sentiment-driven selling.
Sign up to view all
KNSL 12-Month Price Forecast
The assessment is neutral based on the clash between deteriorating price action and resilient underlying financials. The probability-weighted base case suggests limited near-term upside as the stock digests its severe decline. The stance would upgrade to bullish on a confirmed breakout above $400 with supporting margin data, signaling the downtrend has broken. It would turn bearish on a breakdown below $294, which would indicate the fundamental story is indeed cracking. The key near-term monitor is the next earnings report for clarity on margin trajectory.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kinsale Capital Group, Inc.'s 12-month outlook, with a consensus price target around $407.69 and implied upside of +30.0% versus the current price.
Average Target
$407.69
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$251 - $408
Analyst target range
Analyst coverage appears limited, with only two analysts providing estimates according to the data, which is atypical for a company with a $9+ billion market cap and suggests it may be under-followed by the broader institutional research community. The consensus sentiment, inferred from recent institutional rating actions, leans bearish to neutral, with two downgrades to 'Underperform' from Jefferies and BMO Capital in February and March 2026, while firms like JP Morgan and Cantor Fitzgerald maintain 'Neutral' stances, and Truist Securities and Morgan Stanley maintain 'Buy' or 'Overweight' ratings. The wide target range implied by the estimated EPS spread—from a low of $21.63 to a high of $24.27—signals meaningful uncertainty among the few analysts covering the stock regarding the company's future earnings power. The pattern of recent downgrades, coupled with the stock's severe price decline, indicates that analyst sentiment has turned cautious, likely reflecting concerns about the sustainability of its exceptional underwriting margins in a potentially softening insurance market.
Bulls vs Bears: KNSL Investment Factors
The evidence presents a classic battle between deteriorating price sentiment and resilient fundamentals. The bear side currently has stronger momentum, as evidenced by the steep 32.26% annual decline, recent analyst downgrades, and extreme underperformance. However, the bull case is grounded in objectively strong financials: 17%+ revenue growth, a 25.7% ROE, and a forward P/E that has compressed to 14.3x. The single most important tension in the investment debate is whether the market's derating (P/E from 31.6x to 17.97x) is an overreaction to cyclical margin concerns or a justified repricing for a decelerating growth story. The resolution hinges on whether KNSL can sustain its high underwriting profitability in the coming quarters.
Bullish
- Strong Underlying Profitability: KNSL maintains exceptional underwriting discipline, evidenced by a Q4 net margin of 28.68% and a robust Return on Equity of 25.70%. This high profitability, combined with a low debt-to-equity ratio of 0.11, demonstrates a fundamentally strong and efficient business model.
- Compelling Valuation Re-rating: The stock's valuation has compressed dramatically, with its trailing P/E falling from 31.59x to 17.97x over the past year. Its forward P/E of 14.33x and PEG ratio of 0.84 suggest the market is pricing in minimal growth, potentially creating a value opportunity given the company's 17.26% YoY revenue growth.
- Robust Revenue Growth Trajectory: The company continues to post strong top-line growth, with Q4 2025 revenue of $483.27 million representing a 17.26% year-over-year increase. This growth is sustained, with revenue climbing sequentially from $423.40M in Q1 2025 to $483.27M in Q4 2025.
- Strong Cash Flow Generation: KNSL generates significant free cash flow, with a trailing twelve-month figure of $990.05 million. This provides the company with ample financial flexibility to fund growth, withstand competitive pressures, or return capital to shareholders.
Bearish
- Severe Price and Sentiment Downtrend: The stock is in a pronounced downtrend, down 32.26% over the past year and 13.05% over the past month. Recent analyst downgrades to 'Underperform' by Jefferies and BMO Capital reflect growing caution on the stock's prospects.
- Concerns Over Margin Sustainability: While Q4 margins were strong, quarterly operating margins have shown volatility, ranging from 26.53% in Q1 2025 to 36.18% in Q4 2025. This variability fuels market concerns about potential compression in a competitive insurance market.
- Limited Analyst Coverage & High Short Interest: Only two analysts provide estimates, indicating the stock may be under-followed, which can lead to liquidity and visibility issues. A short ratio of 8.5 signals significant professional skepticism about a near-term recovery.
- Valuation Compression Risk Persists: Despite the derating, the stock still trades at a Price/Book of 4.62x and Price/Sales of 4.83x. If growth decelerates, these multiples could compress further, especially if the market continues to de-rate premium-valued financial stocks.
KNSL Technical Analysis
The prevailing price trend is a pronounced and sustained downtrend, with the stock down 32.26% over the past year. Currently trading at $311.29, the price sits just 6.0% above its 52-week low of $293.78, positioning it near the bottom of its annual range, which suggests the stock is deeply oversold and may present a value opportunity, though it also risks being a 'falling knife' if negative sentiment persists. Recent momentum remains sharply negative, with the stock down 13.05% over the past month and 16.17% over the past three months, indicating accelerating downward pressure that aligns with and intensifies the longer-term downtrend. The stock's relative strength is severely weak, underperforming the S&P 500 by 57.45% over the past year and 18.65% over the past month, highlighting significant sector or company-specific headwinds. Key technical support is clearly defined at the 52-week low of $293.78, while resistance is far above at the 52-week high of $512.76; a breakdown below support could trigger further capitulation, while any sustained move above recent highs near $400 would signal a potential trend reversal. With a beta of 0.95, the stock's volatility is roughly in line with the broader market, but its 40.29% maximum drawdown underscores the extreme downside volatility experienced by shareholders recently.
Beta
0.95
0.95x market volatility
Max Drawdown
-40.3%
Largest decline past year
52-Week Range
$294-$513
Price range past year
Annual Return
-33.6%
Cumulative gain past year
| Period | KNSL Return | S&P 500 |
|---|---|---|
| 1m | -13.1% | +3.3% |
| 3m | -17.4% | +6.9% |
| 6m | -15.3% | +12.4% |
| 1y | -33.6% | +23.4% |
| ytd | -20.1% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KNSL Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $483.27 million representing a 17.26% year-over-year increase, continuing a multi-quarter trend of strong double-digit expansion driven by premium growth in its core E&S lines. The sequential trend shows revenue grew from $423.40 million in Q1 2025 to $483.27 million in Q4 2025, indicating sustained demand for its specialty products. The company is highly profitable, with Q4 2025 net income of $138.62 million and a net margin of 28.68%, demonstrating exceptional underwriting discipline. Gross margin for the quarter was a healthy 55.88%, and the operating margin was 36.18%, though margins have shown some quarterly variability, with Q1 2025 operating margin at 26.53% before recovering later in the year, reflecting the inherent volatility of insurance underwriting results. Balance sheet and cash flow health are strong, with a low debt-to-equity ratio of 0.11, indicating minimal financial leverage, and robust free cash flow generation evidenced by a trailing twelve-month FCF of $990.05 million. Return on Equity is an impressive 25.70%, showcasing efficient use of shareholder capital, and the current ratio of 0.84, while below 1, is typical for insurers whose liabilities are primarily long-term claims reserves rather than short-term payables.
Quarterly Revenue
$483271000.0B
2025-12
Revenue YoY Growth
+0.17%
YoY Comparison
Gross Margin
+0.55%
Latest Quarter
Free Cash Flow
$990053000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KNSL Overvalued?
Given the company's substantial profitability with net income of $138.62 million in Q4 alone, the primary valuation metric is the P/E ratio. The trailing P/E stands at 17.97x, while the forward P/E is lower at 14.33x; this gap suggests the market expects earnings growth to continue, albeit at a potentially slower pace than in the past. Compared to industry averages, Kinsale's valuation presents a mixed picture: its trailing P/E of 17.97x is likely at a discount to its historical premium given its high-growth, high-ROE profile, though specific industry average data is not provided in the inputs for direct comparison. The stock's Price/Sales ratio of 4.83x and Price/Book ratio of 4.62x provide additional context for its market valuation relative to its revenue base and equity. Historically, the stock's own valuation has compressed dramatically; for instance, its P/E ratio has fallen from 31.59x at the end of Q1 2025 to 16.26x at the end of Q4 2025, indicating the market has significantly re-rated the stock downward, now trading near the lower end of its recent historical range, which may signal a value opportunity if fundamentals remain intact.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 16x~48x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are currently muted but center on earnings volatility. While the balance sheet is strong with minimal debt (D/E of 0.11), the primary risk is margin compression. Quarterly operating margins have fluctuated from 26.5% to 36.2% over the past year, and a sustained decline towards the lower end of that range could significantly impact the high-multiple valuation. Furthermore, the company's impressive growth and ROE of 25.7% set a high bar; any deceleration could trigger further multiple contraction.
Market & Competitive Risks are elevated. The stock has suffered a severe de-rating, with its P/E compressing by nearly 50% from its high, reflecting a broader shift away from premium-valued growth stocks. With a beta of 0.95, it moves roughly with the market, but its 40.3% maximum drawdown shows it has experienced extreme downside volatility. The key risk is that the competitive E&S insurance market intensifies, pressuring premium rates and underwriting margins, which would validate the market's cautious stance and could lead to further valuation compression towards industry-average multiples.
Worst-Case Scenario involves a combination of competitive pressures leading to a material decline in underwriting margins (e.g., operating margin falling to 25%), coupled with a growth slowdown to single digits. This could trigger additional analyst downgrades and a flight from the stock, pushing it to re-test and break its 52-week low of $293.78. A realistic downside from the current price of $311.29 could be a further 20-25% decline, targeting a range of $230-$250, which would align the P/E multiple closer to 10-12x on depressed earnings, reflecting a loss of its growth premium entirely.
FAQ
The primary risks are, in order of severity: 1) Sentiment & Momentum Risk: The stock is in a severe downtrend, down 32% YoY, and negative sentiment could persist regardless of fundamentals. 2) Margin Compression Risk: Quarterly operating margins have shown volatility (26.5% to 36.2%); a sustained decline would cripple the high-ROE thesis. 3) Competitive/Market Risk: Increased competition in the E&S insurance space could pressure premium rates and growth. 4) Liquidity & Coverage Risk: With only two analyst estimates, the stock is under-followed, which can exacerbate price swings on news.
The 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $340 and $390 as it consolidates, assuming steady execution. The Bull Case (30% probability) projects a rally to $450-$512 if margins stabilize and sentiment reverses. The Bear Case (20% probability) warns of a drop to $250-$294 if fundamentals deteriorate. The base case is most likely, implying modest upside from current levels but significant uncertainty. The key assumption for this outlook is that KNSL's underwriting margins do not experience a material, sustained decline in the next two quarters.
KNSL appears undervalued relative to its own historical trading range and growth profile, but fairly valued given current market sentiment. Its forward P/E of 14.33x and PEG ratio of 0.84 are low for a company growing revenue at 17%+ with a 25.7% ROE. This represents a steep discount to its trailing P/E of 31.6x from a year ago. However, the market is applying a discount due to fears of margin compression and competitive pressures. The valuation implies the market expects significant earnings growth deceleration. If the company can sustain its current performance, the stock is likely undervalued.
KNSL presents a high-conviction value opportunity for patient investors but carries significant near-term risk. The stock is deeply oversold, down 32.3% in a year and trading near its 52-week low, while the underlying business generates 17% revenue growth and a 25.7% ROE at a forward P/E of just 14.3x. However, with recent analyst downgrades, a high short interest of 8.5, and negative momentum, it is not a good buy for short-term traders or risk-averse investors. It is a good buy for long-term, valuation-sensitive investors willing to wait for a fundamental or technical catalyst to reverse the negative sentiment.
KNSL is unsuitable for short-term trading due to its high volatility (40.3% max drawdown), negative momentum, and high short interest, which can cause sharp swings. It is a candidate for a long-term (3+ year) investment for investors who believe the current valuation disconnect will correct as the company's fundamental strength becomes apparent again. The stock does not pay a meaningful dividend (yield 0.17%), so the thesis is purely capital appreciation. Given the need for the technical and sentiment picture to stabilize, a minimum holding period of 12-18 months is suggested to allow the investment thesis to play out.